On August 19, 2026, Moderna, Inc. (NASDAQ:MRNA) and Merck & Co., Inc. (NYSE:MRK) said their personalized melanoma vaccine, intismeran, combined with Merck’s Keytruda, met its goals in a Phase 3 trial of 1,137 patients. It reduced the risk of cancer recurrence and spread compared with Keytruda alone, Reuters reported.
It is the first positive late-stage trial result for an mRNA cancer vaccine. Merck’s Jane Healy called the result a “clinically meaningful improvement,” and said it was well tolerated, CNBC reported.
Both companies’ shares rose on the news. Full data will be presented at an upcoming medical meeting alongside regulatory filing discussions. The companies are already running additional trials of the same vaccine-Keytruda combination in lung, bladder, kidney, pancreatic, and stomach cancers.
Bull Case
For Moderna, Inc. (NASDAQ:MRNA), this is proof that its mRNA platform works beyond vaccines for infectious disease. A positive Phase 3 readout validates years of personalized cancer vaccine development. It gives Moderna a genuine second growth pillar alongside its COVID business, one built on technology the company already knows how to manufacture and scale.
For Merck & Co., Inc. (NYSE:MRK), the result extends Keytruda’s competitive life at a critical moment. Pairing Keytruda with a personalized vaccine gives Merck a differentiated, harder-to-copy combination therapy just as Keytruda itself approaches patent expiration later this decade. Hence, it protects franchise revenue through a next-generation product rather than the drug alone.
The pipeline behind this result is broad, not a single bet, since the firms are already running trials of the same vaccine-Keytruda combination in lung, bladder, kidney, pancreatic, and stomach cancers, Reuters reported. A platform technology that succeeds in melanoma and can be redirected at other tumor types by changing the targeted mutations offers multiple additional shots at approval rather than one binary outcome.
Bear Case
This is still one trial in one cancer type, not an approved product. Regulatory filings are only now beginning, which means approval, pricing, and reimbursement decisions remain ahead. each a point where the current enthusiasm could cool if later data or regulatory review raises new questions.
For Moderna, Inc. (NASDAQ:MRNA) specifically, the financial stakes are more concentrated than for Merck. Moderna is a smaller company whose commercial success still depends heavily on execution in oncology now that COVID vaccine demand has faded. So any delay or setback in this program carries more relative weight for Moderna’s results than for a diversified pharmaceutical company the size of Merck & Co., Inc. (NYSE:MRK).
The treatment requires real infrastructure most cancer centers do not yet have. Building a personalized vaccine means sequencing each patient’s tumor, identifying unique mutations, and manufacturing an individualized product before treatment can begin. It is a logistical and cost burden that could limit how quickly the therapy reaches patients even after approval, particularly outside major research hospitals.
Conclusion
This result matters to both companies, but a big opportunity is not the same as a guaranteed win. For Moderna, the best-case scenario is proving its mRNA technology works in cancer rather than just vaccines. Its worst-case scenario is relying too much on one young product line for its future growth. For Merck, the best-case scenario is protecting its market lead with Keytruda before its patent expires. Its worst-case scenario is that this success stays just one trial, in one cancer type, across a huge portfolio.
Overall, hedge funds favor Merck over Moderna. Insider Monkey’s hedge fund database shows Merck & Co., Inc. (NYSE:MRK) was held by 101 hedge funds as of Q2 2026, up from 98. Moderna, Inc. (NASDAQ:MRNA) was held by 49, down from 52.
READ NEXT: Warren Buffett “Blew It” on Alphabet (GOOGL) And Made It Berkshire’s Third-Biggest Bet and Sony Group (SONY) and Taiwan Semiconductor (TSM) Are Betting $4.7 Billion on the “Eyes” of AI Machines.
Disclosure: None. This article is originally published at Insider Monkey.
